A vs. UTHR: Agilent vs. United Therapeutics Stock Comparison

November 11, 2026

How do Agilent (A) and United Therapeutics (UTHR) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Agilent (A) and United Therapeutics (UTHR) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but A is classified in Life Sciences Tools & Services while UTHR is classified in Biotechnology.

Company profile comparison for Agilent (A) and United Therapeutics (UTHR)
Profile Item	A	UTHR
Name	AgileThought, Inc. Class A Common Stock	United Therapeutics Corporation
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Life Sciences Tools & Services	Biotechnology
GICS Sub-Industry	Life Sciences Tools & Services	Biotechnology
Market Capitalization	49.28 billion USD	23.94 billion USD
Currency	USD	USD
Exchange	NYSE	Nasdaq
Listing Date	November 18, 1999	June 17, 1999
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

UTHR

GSPC

Agilent (A) vs. United Therapeutics (UTHR), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Agilent (A) and United Therapeutics (UTHR). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Agilent (A) and United Therapeutics (UTHR). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Agilent (A) and United Therapeutics (UTHR)
Metric	A	UTHR
Total Return (1Y)	22.92%	28.77%
Total Return (3Y, Annualized)	19.33%	37.63%
Total Return (5Y, Annualized)	3.03%	23.78%

Risk Profile

Drawdown History

UTHR

GSPC

Agilent (A) vs. United Therapeutics (UTHR), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Agilent (A) and United Therapeutics (UTHR). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Agilent (A) and United Therapeutics (UTHR)
Metric	A	UTHR
Volatility (1Y, Annualized)	33.10%	35.00%
Beta (5Y)	1.22	0.49
Max Drawdown (5Y)	-38.09%	-33.00%
Avg. Volume (3M)	2.25M	694.55K

Risk-Adjusted Performance

Risk-Return Positioning

A and UTHR are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Agilent (A) and United Therapeutics (UTHR)
Metric	A	UTHR
Sharpe Ratio (1Y)	0.56	0.70
Sortino Ratio (1Y)	0.96	1.29

Profitability

ROE (TTM)

Both Agilent (A) at 20.97% and United Therapeutics (UTHR) at 19.13% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.97%

Max: 109.18%
A: 20.97%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.13%

Max: 109.18%
UTHR: 19.13%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Agilent (A) vs. United Therapeutics (UTHR): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Both Agilent (A) at 19.53% and United Therapeutics (UTHR) at 38.61% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.53%

A: 19.53%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

38.61%

UTHR: 38.61%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Agilent (A) vs. United Therapeutics (UTHR): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Agilent (A) at 25.56% and United Therapeutics (UTHR) at 28.99% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.56%

Max: 83.12%
A: 25.56%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

28.99%

Max: 83.12%
UTHR: 28.99%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Agilent (A) vs. United Therapeutics (UTHR): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Agilent (A) and United Therapeutics (UTHR)
Metric	A	UTHR
ROE (TTM)	20.97%	19.13%
ROA (TTM)	8.63%	10.91%
Net Margin (TTM)	19.53%	38.61%
Operating Margin (TTM)	25.56%	28.99%
Gross Margin (TTM)	53.65%	86.34%

Growth

Revenue Growth

Both Agilent (A) at 6.73% and United Therapeutics (UTHR) at 10.61% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Agilent (A) vs. United Therapeutics (UTHR): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both Agilent (A) at 3.16% and United Therapeutics (UTHR) at 13.07% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Agilent (A) vs. United Therapeutics (UTHR): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Agilent (A) and United Therapeutics (UTHR)
Metric	A	UTHR
Revenue Growth (YoY)	6.73%	10.61%
Revenue Growth (3Y CAGR)	0.48%	18.02%
EPS Growth (YoY)	3.16%	13.07%
EPS Growth (3Y CAGR)	3.02%	22.92%

Financial Strength

Current Ratio (MRQ)

United Therapeutics (UTHR) at 4.61 keeps current ratio within its industry’s typical mid-range, while Agilent (A) at 2.05 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for A.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.05

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
A: 2.05
Min: 0.10

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.61

Max: 25.13
Q3: 12.13
Median: 5.52
UTHR: 4.61
Q1: 2.47
Min: 0.10

Agilent (A) vs. United Therapeutics (UTHR): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Only one side’s leverage can be read here: Agilent (A) carries debt-to-equity ratio of 0.56 against its industry range, while United Therapeutics (UTHR) reports no figure this period.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.56

Max: 1.42
Q3: 0.65
A: 0.56
Median: 0.15
Q1: 0.02
Min: 0.00

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00
UTHR: --

Agilent (A) vs. United Therapeutics (UTHR): UTHR does not report debt-to-equity ratio, so it has no value marker; A is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Financial Strength Metrics

Financial strength metrics for Agilent (A) and United Therapeutics (UTHR)
Metric	A	UTHR
Current Ratio (MRQ)	2.05	4.61
Debt / Equity (MRQ)	0.56	--
Net Debt / EBITDA	1.15	-1.53

Dividends

Dividend Yield (TTM)

United Therapeutics (UTHR) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Agilent (A) reports a yield of 0.59%, ranking against industry peers normally.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.59%

A: 0.59%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

UTHR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Agilent (A) vs. United Therapeutics (UTHR): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

United Therapeutics (UTHR) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Agilent (A) reports a payout of 19.98%, ranking against industry peers normally.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.98%

A: 19.98%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

UTHR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Agilent (A) vs. United Therapeutics (UTHR): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Agilent (A) and United Therapeutics (UTHR)
Metric	A	UTHR
Dividend Yield (TTM)	0.59%	0.00%
Dividend Payout Ratio (TTM)	19.98%	0.00%

Valuation

P/E Ratio (TTM)

Both Agilent (A) at 34.47 and United Therapeutics (UTHR) at 21.22 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

34.47

Max: 85.34
Q3: 43.46
A: 34.47
Median: 26.69
Q1: 13.30
Min: 0.07

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

21.22

Max: 85.34
Q3: 43.46
Median: 26.69
UTHR: 21.22
Q1: 13.30
Min: 0.07

Agilent (A) vs. United Therapeutics (UTHR): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Agilent (A) at 6.68 and United Therapeutics (UTHR) at 7.51 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.68

Max: 58.18
Q3: 25.77
Median: 7.30
A: 6.68
Q1: 3.01
Min: 0.01

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.51

Max: 58.18
Q3: 25.77
UTHR: 7.51
Median: 7.30
Q1: 3.01
Min: 0.01

Agilent (A) vs. United Therapeutics (UTHR): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

United Therapeutics (UTHR) at 3.80 is valued about in line with its industry on P/B ratio, while Agilent (A) at 6.69 carries an above-peer premium to book — A is pricier on assets.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.69

Max: 13.53
A: 6.69
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.80

Max: 13.53
Q3: 6.54
UTHR: 3.80
Median: 3.25
Q1: 1.69
Min: -5.59

Agilent (A) vs. United Therapeutics (UTHR): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Agilent (A) and United Therapeutics (UTHR)
Metric	A	UTHR
P/E Ratio (TTM)	34.47	21.22
P/S Ratio (TTM)	6.68	7.51
P/B Ratio (MRQ)	6.69	3.80
Free Cash Flow Yield (TTM)	2.15%	1.90%